23andMe recordsdata for chapter safety

Well-liked DNA testing agency 23andMe has filed for chapter safety, and introduced that its co-founder and CEO, Anne Wojcicki, has resigned with quick impact.

The corporate will now try and promote itself below the supervision of a court docket.

23andMe mentioned in a press launch that it plans to proceed working all through the sale course of and that there “are not any modifications to the way in which the corporate shops, manages, or protects buyer information.”

On Friday, the Legal professional Normal in 23andMe’s dwelling state of California issued a client alert advising prospects to delete their information from the location given the corporate’s “reported monetary misery.”

23andMe’s saliva-based take a look at kits have been as soon as celebrated amongst prospects and traders, who helped to push the corporate’s worth as excessive as $6bn (£4.6bn).

However it has been struggling for survival.

Based in 2006, the corporate went public in 2021 however has by no means turned a revenue.

In September, the agency settled a lawsuit alleging that it failed to guard the privateness of almost seven million prospects whose private data was uncovered in a 2023 information breach.

In some circumstances, hackers gained entry to household bushes, beginning years and geographic areas, by utilizing prospects’ previous passwords. The information stolen didn’t embody DNA information, in response to the corporate.

Two months after the settlement, it minimize 200 workers, amounting to 40% of its workforce.

23andMe mentioned its finance chief, Joe Selsavage, will take over as interim chief government.

Ms Wojcicki will proceed to function a member of the board.

She had tried to take the corporate personal however was not open to a third-party takeover.

23andMe – which as soon as had high-profile endorsements from the likes of Oprah Winfrey, Eva Longoria, and Snoop Dogg – struggled to redefine its enterprise mannequin.

Clients didn’t have a lot to return for as soon as they’d paid for a DNA report, and an effort to launch a subscription service proved unsuccessful.

Efforts to make use of its huge trove of knowledge to maneuver into drug improvement additionally faltered.

All the firm’s administrators, apart from Ms Wojcicki resigned final summer season, saying in a letter they have been quitting after not receiving a passable buyout provide from her.